Health officials in the U.S. have rejected the approval of this monumental diabetic drug due to adverse cardiovascular effects. The European Union (EU), on the other hand, is embracing it with open arms.
Tresiba, a drug designed by Novo Nordisk to treat Type 1 diabetes, was approved by EU in 2013, and is currently in developmental clinical trials. According to a news report from Reuters, the pharmaceutical company recently announced that Tresiba was tested to be safe and effective for children up to 18 years of age. “These data show that Tresiba has the potential to offer youngsters with diabetes a new treatment option, which may help them achieve better control of their diabetes,” said Dr. Nandu Thalange of U.K.’s Norfolk and Norwich University Hospital and one of the lead study authors.
The clinical trial was conducted on 350 youngsters with Type 1 diabetes. Results were favorable based on diabetes tests: blood sugar levels of the patients who received Tresiba were improved without decreasing the level too much to cause hypoglycemia. Results also showed that the fasting plasma glucose dropped significantly after the patients took Tresiba.
Diabetes continues to be one of the most widely spread diseases in the U.S., with close to 30 million already diagnosed with the blood sugar abnormality. Global figures from the World Health Organization show that only 10 percent of diabetics in the whole world are diagnosed with Type 1 diabetes, which usually occurs in children.
[ Image source ]